Pay in 4 interest-free payments of $6.95 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
Novo Nordisk ended its type 1 diabetes program for Victoza in 2015 because the A1c lowering effects were too small (decrease of ~0.2%-0.3%)
This evolving competition is expected to drive innovation in areas such as delivery devices, patient adherence tools, and real-world clinical data generation
Da rt sm mu: Sau 6 thng 12 thng s dng
Risks of incident cardiovascular disease associated with concomitant elevations in lipoprotein(a) and low-density lipoprotein cholesterol-the Framingham Heart Study
US$ 28.70
US$ 25.58
US$ 27.21
:max_bytes(150000):strip_icc()/health-GettyImages-2025836701-ce3f5ccf0f98428e9d14abaeb07ba307.jpg)
US$ 28.92
US$ 21.14
US$ 21.86
